Navigation Links
Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
Date:11/16/2009

hod used during the Adiana procedure. Primary investigators will present new data from studies on the Adiana system.

Approved by the Food and Drug Administration (FDA) in July 2009, the Adiana procedure is indicated for women who desire permanent birth control by occlusion of the fallopian tubes.

Ideal candidates include women who do not want children in the future and would like the peace of mind and convenience of permanent birth control.

Sessions for information and key findings about Adiana at AAGL include:

  • "Adiana System for Transcervical Sterilization: 3-Year Efficacy Results;" presented by T.L. Anderson, T.G. Vancaillie; Open Communications; 6 -- Hysteroscopy (Wednesday, 11/18 at 11:48 pm)
  • "Mechanism of Action of the Adiana Device: A Histologic Perspective;" presented by T.G. Vancaillie, D. Harrington, V. Carr-Brendel, J. Anderson; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:44 pm)
  • "Evaluating the Learning Curve for a Novel Hysteroscopic Sterilization Technique;" presented by M.Y. Bongers, S. Veersema; Open Communications; 16 -- Hysteroscopy (Thursday, 11/19 at 8:12 am)
  • "Feasibility of Hysterosalpingography To Evaluate Tubal Occlusion Following Concomitant Adiana(®) Transcervical Sterilization and NovaSure(®) Endometrial Ablation;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Poster Presentation
  • "Concominant Use of Adiana(®) Permanent Contraception and NovaSure(®) Impedance Controlled Endometrial Ablation: A Peri-Hysterectomy Study;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:26 pm)

About Hologic, Inc
'/>"/>

SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... of the commonly used stimulant methylphenidate (Ritalin) to speed ... the inhaled gas isoflurane, as previously reported, and to ... Massachusetts General Hospital (MGH) research team that reported the ... the May issue of Anesthesiology, and their ...
... HealthDay Reporter , THURSDAY, April 5 (HealthDay News) -- ... crops eaten by U.S. consumers is linked to shorter ... pesticides are known as organophosphates, which kill insects by ... nerve poisons during World War II, they can disrupt ...
... Serena Gordon HealthDay Reporter , THURSDAY, April 5 ... cells that potentially grow into tumors has been one of ... researchers from the Children,s Hospital of Philadelphia have generated a ... at least for stem cells destined for the digestive system ...
... largest multicenter clinical trial of children undergoing early-stage ... management did not significantly affect neurodevelopmental outcomes at ... were innate patient characteristics and general medical morbidity ... Children born with hypoplastic left-heart syndrome (HLHS) ...
... PhD, is the 2012 recipient of Kessler Foundation,s Joel A. ... the Field of Physical Medicine & Rehabilitation (PM&R). Dr. Whyte ... in West Orange on May 10. The award includes a ... Dr. Whyte is the founding director of Moss Rehabilitation ...
... Stem Cell , a Cell Press publication, have found a ... advance in mice suggests that a combination approach to therapy ... That,s in contrast to the vast majority of CML patients ... into remission only to see their cancer return again. It ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: